PUBLIC COMPANY
save$MDCXMedicus Pharma Ltd.
$MDCX0.3842+2.59%W. Conshohocken, PA, USupdated 2mo ago
community read0 votes
🐶 often sniffed alongside
top 3pipeline
0
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Ionis’ rare neurology drug approved; Pfizer inks an ADC dealZanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.biopharma_dive · 1mo ago
- Pfizer punts Seagen ADC, further muddying value of the $43B buyoutThe co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of th…biospace · 1mo ago
- Pfizer shares ADC rights with Medicus; RevMed updates lung cancer dataPlus, news about Novartis. 🤝 Pfizer turns over ADC: The New York pharma is giving Medicus Pharma co-development rights to a CD228-targeted antibody-drug conjugate known as PF-08046031, a Seagen-de…endpoints · 1mo ago
- Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ dealPfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier this year.fiercebiotech · 1mo ago
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that